Keryx Biopharmaceuticals, Inc. (KERX) Receives Orphan Drug Status for Perifosine
Keryx Biopharmaceuticals, Inc. reported that one of its drug candidates used to treat cancer received a major boost towards development through the regulatory actions of the U.S. government. Keryx Biopharmaceuticals, Inc. said that KRX-0401, also known as Perifosine, was designated an Orphan Drug by the United States Food and Drug Administration. This designation is available only for drugs used to treat illnesses affecting less than 200,000 individuals, and gives the company a seven year exclusive marketing term in the United States. Keryx Biopharmaceuticals, Inc. is developing Perifosine as a therapy for the treatment of neuroblastoma, a cancer that affects the…